12:00 AM
 | 
Mar 26, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Pulmaquin liposomal ciprofloxacin: Phase III start

This year, Aradigm will begin a double-blind, placebo-controlled, international Phase III trial to evaluate 210 mg inhaled Pulmaquin daily for 28 days and then 28 days off for 6 cycles...

Read the full 130 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >